Innodem Neurosciences’ ETNA Designated an FDA Breakthrough Device for MS

Innodem Neurosciences’ ETNA mobile eye tracking technology for multiple sclerosis (MS) patients has been designated a Breakthrough Device by the FDA.

The software app records eye movements to help estimate the severity and track the progression of the disease. It is intended for individuals with a diagnosis of MS who have oculomotor symptoms.

The app runs off-the-shelf electronic tablets, turning them into devices that capture eye movements. It can then remotely inform clinicians about MS disease progression so they can adjust treatment and improve patient outcomes.